Clinical Trial Update: Study to Evaluate Broadlumab vs Placebo and Ustekinumab [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Broadlumab versus placebo and Ustekinumab for psoriasis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Broadlumab (Broadlumab)
• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: MedDerm Associates | Conditions: Psoriasis | Phase 3 | Status: TERMINATED